The UK's Argenta Discovery and contract research organization PRECOS have entered into an alliance to provide cancer drug discovery services. Christopher Ashton, chief executive of Argenta, said: "Argenta has partnered with PRECOS to provide clients with dedicated access to specialist in vitro, ex vivo and in vivo cancer models and expertise, offered by a world leader in the field. We have several ongoing cancer-focused contract research programs and a number of projects in the pipeline, which are likely to benefit from PRECOS' support and know-how."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze